Search

Your search keyword '"Pautasso, Chiara"' showing total 18 results
Start Over Author "Pautasso, Chiara"
18 results on '"Pautasso, Chiara"'

3. Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study

Author

Larocca, Alessandra, primary, Salvini, Marco, additional, De Paoli, Lorenzo, additional, Cascavilla, Nicola, additional, Benevolo, Giulia, additional, Galli, Monica, additional, Montefusco, Vittorio, additional, Caravita di Toritto, Tommaso, additional, Baraldi, Anna, additional, Spada, Stefano, additional, Giuliani, Nicola, additional, Pautasso, Chiara, additional, Pulini, Stefano, additional, Ronconi, Sonia, additional, Pescosta, Norbert, additional, Liberati, Anna Marina, additional, Patriarca, Francesca, additional, Cellini, Claudia, additional, Tosi, Patrizia, additional, Offidani, Massimo, additional, Cavo, Michele, additional, Palumbo, Antonio, additional, Boccadoro, Mario, additional, and Bringhen, Sara, additional

Published
2018
Full Text
View/download PDF

5. Long Term Outcome of Lenalidomide-Dexamethasone (Rd) Vs Melphalan-Lenalidomide-Prednisone (MPR) Vs Cyclophosphamide-Prednisone-Lenalidomide (CPR) As Induction Followed By Lenalidomide-Prednisone (RP) Vs Lenalidomide (R) As Maintenance in a Community-Based Newly Diagnosed Myeloma Population: Updated Analysis of EMN01 Phase III Study

Author

Bringhen, Sara, primary, Offidani, Massimo, additional, Musto, Pellegrino, additional, Liberati, Anna Marina, additional, Benevolo, Giulia, additional, Cascavilla, Nicola, additional, Genuardi, Mariella, additional, Gaidano, Gianluca, additional, Zamagni, Donatella, additional, Ferrando, Paola, additional, Pizzolo, Giovanni, additional, Derudas, Daniele, additional, Gambella, Manuela, additional, Dominietto, Alida, additional, Annibali, Ombretta, additional, De Sabbata, Giovanni Maria, additional, Gabbas, Attilio, additional, Musolino, Caterina, additional, Pautasso, Chiara, additional, Zambello, Renato, additional, La Nasa, Giorgio, additional, Maracci, Laura, additional, Palumbo, Antonio, additional, Hájek, Roman, additional, and Boccadoro, Mario, additional

Published
2017
Full Text
View/download PDF

7. Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy

Author

Oliva, Stefania, primary, Gambella, Manuela, additional, Larocca, Alessandra, additional, Spada, Stefano, additional, Marzanati, Eleonora, additional, Mantoan, Barbara, additional, Grammatico, Sara, additional, Conticello, Concetta, additional, Gamberi, Barbara, additional, Offidani, Massimo, additional, Liberati, Anna Marina, additional, Pautasso, Chiara, additional, Omedé, Paola, additional, Palumbo, Antonio, additional, and Boccadoro, Mario, additional

Published
2016
Full Text
View/download PDF

8. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis

Author

Oliva, Stefania, primary, Gambella, Manuela, additional, Gilestro, Milena, additional, Muccio, Vittorio Emanuele, additional, Gay, Francesca, additional, Drandi, Daniela, additional, Ferrero, Simone, additional, Passera, Roberto, additional, Pautasso, Chiara, additional, Bernardini, Annalisa, additional, Genuardi, Mariella, additional, Patriarca, Francesca, additional, Saraci, Elona, additional, Petrucci, Maria Teresa, additional, Pescosta, Norbert, additional, Liberati, Anna Marina, additional, Caravita, Tommaso, additional, Conticello, Concetta, additional, Rocci, Alberto, additional, Musto, Pellegrino, additional, Boccadoro, Mario, additional, Palumbo, Antonio, additional, and Omedè, Paola, additional

Published
2016
Full Text
View/download PDF

11. Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma

Author

Salvini, Marco, Troia, Rossella, Giudice, Davide, Pautasso, Chiara, Boccadoro, Mario, and Larocca, Alessandra

Abstract

ABSTRACTIntroduction: multiple myeloma (MM) is a plasma cell disorder that represents the second most frequent hematologic cancer. Although MM is still an incurable disease, prognosis has improved in the last decades thanks to the introduction of novel agents such as proteasome inhibitors (PIs), immunomodulatory drugs, monoclonal antibodies, and histone deacetylase inhibitors.Areas covered: ixazomib is the first oral PI recently approved by Food and Drug Administration (FDA) and European Medicine Agency (EMA) in combination with lenalidomide and dexamethasone as salvage therapy in MM patients. In this paper, we focus on its pharmacokinetics features, as well as its safety and efficacy in clinical studies.Expert opinion: ixazomib can be considered an oral analogue of bortezomib, with 9.5-day half-life, 58% of oral bioavailability, and a large distribution volume of 543L. These features make it a versatile molecule, potentially useful both in combination and as single agent. Oral route of administration and good efficacy/safety profile are its winning characteristics, providing the rationale for a future role also in the maintenance setting.

Published
2018
Full Text
View/download PDF

13. Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients

Author

Palumbo, Antonio, primary, Bringhen, Sara, additional, Rossi, Davide, additional, Cavalli, Maide, additional, Ria, Roberto, additional, Gentilini, Silvia, additional, Patriarca, Francesca, additional, Nozzoli, Chiara, additional, Levi, Anna, additional, Guglielmelli, Tommasina, additional, Benevolo, Giulia, additional, Vincelli, Donatella, additional, Baldini, Luca, additional, Morabito, Fortunato, additional, Grasso, Mariella, additional, Marasca, Roberto, additional, Rizzo, Manuela, additional, Pautasso, Chiara, additional, Falcone, Antonietta Pia, additional, Gottardi, Daniela, additional, Montefusco, Vittorio, additional, Musolino, Caterina, additional, Cangialosi, Clotilde, additional, Mansueto, Giovanna, additional, Liberati, Anna Marina, additional, Magarotto, Valeria, additional, Omedè, Paola, additional, Musto, Pellegrino, additional, Petrucci, Maria Teresa, additional, and Boccadoro, Mario, additional

Published
2012
Full Text
View/download PDF

15. Association of RAMP 1 rs7590387 With the Risk of Migraine Transformation Into Medication Overuse Headache.

Author

Cargnin, Sarah, Pautasso, Chiara, Viana, Michele, Sances, Grazia, Mittino, Daniela, Cantello, Roberto, Tassorelli, Cristina, Nappi, Giuseppe, and Terrazzino, Salvatore

Subjects
*ANALYSIS of covariance, *CALCITONIN, *DISEASE susceptibility, *GENETIC polymorphisms, *HEADACHE, *MIGRAINE, *PEPTIDES, *POLYMERASE chain reaction, *PROBABILITY theory, *PSYCHOLOGICAL tests, *SEROTONIN uptake inhibitors, *STATISTICS, *SUBSTANCE abuse, *TRYPTAMINE, *SUMATRIPTAN, *SEROTONIN agonists, *LOGISTIC regression analysis, *DATA analysis, *TREATMENT effectiveness, *ELETRIPTAN, *DATA analysis software, *DESCRIPTIVE statistics, *GENOTYPES, *DISEASE complications
Abstract

Objectives/Background We herein investigated the role of polymorphisms in calcitonin gene-related peptide ( CGRP)-related genes looking at the association of rs3781719 ( T > C) in the calcitonin gene-related polypeptide-alpha ( CALCA) gene and of rs3754701 ( T > A) and rs7590387 ( C > G) at the receptor activity modifying 1 ( RAMP 1) locus with triptan response in patients with migraine without aura ( MwoA). In addition, their role was evaluated as risk factors for transformation of episodic migraine into medication overuse headache ( MOH). The CGRP has a central role in the pathogenesis of migraine; however, little information is currently available concerning the role of polymorphisms in CGRP-related genes as determinants of clinical response to anti-migraine drugs or as risk factors for migraine chronification. Methods Genotyping was conducted retrospectively by real-time polymerase chain reaction allelic discrimination assay in 219 patients with MwoA and 130 with MOH in whom migraine was the primary headache type. Gene variants association was evaluated by logistic regression analysis adjusted by confounding factors. The threshold of statistical significance was set according to the total number of polymorphisms analyzed in the current study and in previous publications arising from overlapping datasets. Results No evidence of association was found between the three polymorphisms tested and triptan response in MwoA patients. Conversely, carriers of RAMP 1 rs7590387 GG displayed a lower risk of episodic migraine transformation into MOH (vs C allele carriers, odds ratio [ OR]: 0.27, 95% confidence interval [ CI]: 0.13-0.57, P = 0.0002; threshold of significance set at P < 0.0029). When genotype distribution for RAMP 1 rs7590387 was compared between healthy controls (n = 209) and MOH patients, carriers of rs7590387 GG were found at lower risk of developing MOH ( OR: 0.43, 95% CI: 0.22-0.85, P = 0.011). Conclusion These results suggest that RAMP 1 rs7590387 may have a role in the transformation of episodic migraine into MOH. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

16. The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomibfor the treatment of multiple myeloma

Author

Pautasso, Chiara, Bringhen, Sara, Cerrato, Chiara, Magarotto, Valeria, and Palumbo, Antonio

Abstract

Introduction:The development of novel agents, such as immunomodulatory drugs and proteasome inhibitors, has led to a considerable increment in the response rate (RR) and outcomes for multiple myeloma (MM) patients. Unfortunately, MM patients will inevitably relapse and become resistant to new drugs. This led to the continuous development of novel agents. Carfilzomibis a second-generation proteasome inhibitor, demonstrating promising results in relapsed/refractory (RR) and newly diagnosed (ND) MM patients.Areas covered:Herein, the authors review Phase I and II trials on carfilzomib for the treatment of MM. They also describe the profile of the drug during Phase I escalating doses and evaluate the efficacy of carfilzomib both alone and in combination. Finally, the authors also review and discuss the carfilzomib safety profile.Expert opinion:Clinical trials (Phases I and II) with carfilzomib, used both as single agent or in combination with other therapies, established the maximum tolerated dose and recommended schedule of administration. Preliminary data showed that it had a high efficacy and a good safety profile both in RRMM and NDMM patients. Carfilzomib seems to be effective in patients previously treated with bortezomib. Future Phase II and III studies will better define the role of carfilzomib in the treatment of MM as well as its optimum dose.

Published
2013
Full Text
View/download PDF

17. Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomidefor the treatment of multiple myeloma

Author

Bringhen, Sara, Gay, Francesca, Pautasso, Chiara, Cerrato, Chiara, Boccadoro, Mario, and Palumbo, Antonio

Abstract

Introduction:Lenalidomideis an oral immunomodulatory drug, which was recently introduced for the treatment of multiple myeloma (MM). It has been used for the treatment of newly diagnosed and relapsed MM patients, as both maintenance and preventive therapy. Available data show a progression-free survival and overall survival improvement associated with this drug.Areas covered:Efficacy results of lenalidomide in Phase I, II, and III trials in MM are reported herein. The recent use of lenalidomide as maintenance and preventive therapy is described. An overview of the most important adverse events is also presented, such as myelosuppression, thromboembolic events, fatigue, dermatologic toxicity, infections, teratogenic potential, and second primary malignancies. The literature reviewed consists of clinical trials published from 2001 to 2012.Expert opinion:Lenalidomide is one of the most important therapeutic agents for MM treatment. Various trials have confirmed its remarkable anticancer activity, alone or combined with high- or low-dose dexamethasone, or other drugs. Lenalidomide-related adverse events can be controlled with dose reductions, supportive therapy, and appropriate prophylaxis.

Published
2012
Full Text
View/download PDF

18. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.

Author

Oliva S, Gambella M, Gilestro M, Muccio VE, Gay F, Drandi D, Ferrero S, Passera R, Pautasso C, Bernardini A, Genuardi M, Patriarca F, Saraci E, Petrucci MT, Pescosta N, Liberati AM, Caravita T, Conticello C, Rocci A, Musto P, Boccadoro M, Palumbo A, and Omedè P

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Consolidation Chemotherapy, Disease Progression, Female, Humans, Lenalidomide, Maintenance Chemotherapy, Male, Middle Aged, Multiple Myeloma genetics, Multiple Myeloma pathology, Neoplasm, Residual, Prospective Studies, Thalidomide administration & dosage, Thalidomide therapeutic use, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Biomarkers, Tumor genetics, Multiple Myeloma therapy, Thalidomide analogs & derivatives, Transplantation, Autologous methods
Abstract

We analyzed 50 patients who achieved at least a very good partial response in the RV-MM-EMN-441 study. Patients received consolidation with autologous stem-cell transplantation (ASCT) or cyclophosphamide-lenalidomide-dexamethasone (CRD), followed by Lenalidomide-based maintenance. We assessed minimal residual disease (MRD) by multi-parameter flow cytometry (MFC) and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR) after consolidation, after 3 and 6 courses of maintenance, and thereafter every 6 months until progression. By MFC analysis, 19/50 patients achieved complete response (CR) after consolidation, and 7 additional patients during maintenance. A molecular marker was identified in 25/50 patients, 4/25 achieved molecular-CR after consolidation, and 3 additional patients during maintenance. A lower MRD value by MFC was found in ASCT patients compared with CRD patients (p=0.0134). Tumor burden reduction was different in patients with high-risk vs standard-risk cytogenetics (3.4 vs 5.2, ln-MFC; 3 vs 6 ln-PCR, respectively) and in patients who relapsed vs those who did not (4 vs 5, ln-MFC; 4.4 vs 7.8 ln-PCR). MRD progression anticipated clinical relapse by a median of 9 months while biochemical relapse by a median of 4 months. MRD allows the identification of a low-risk group, independently of response, and a better characterization of the activity of treatments.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results